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Objective: To deal with the anti-uropathogenic and in silico screening of (E-)-N0-
(substituted-benzylidene)-2-(quinolin-8-yloxy)acetohydrazide analogues in order to
search the potential anti-uropathogenic agents.
Methods: Three (E-)-N0-(substituted-benzylidene)-2-(quinolin-8-yloxy)acetohydrazide
analogues were synthesized. Structure elucidation was done using various spectroscopic
techniques including infrared radiation, 1hydrogen-nuclear magnetic resonance, carbon-
13 nuclear magnetic resonance, etc. Physicochemical score, bioactivity score and mo-
lecular docking studies were carried out using Lipinski's rule of ﬁve, Molinspiration (web
based software), Autodock 4.2 tools. In vitro anti-uropathogenic activity was carried out
against four pathogens named as Staphylococcus aureus (S. aureus), Staphylococcus
epidermidis, Proteus mirabilis and Escherichia coli by disc diffusion method and macro-
dilution test following their morphological and biochemical characterization.
Results: The formation of (E-)-N0-(substituted-benzylidene)-2-(quinolin-8-yloxy)aceto-
hydrazide is conﬁrmed from the spectroscopic results. All the compounds were found in
compliance with Lipinski's rule of ﬁve and exhibited bioactivity score from −0.50 to 0.00.
Docking results revealed that compound-1 is forming one hydrogen bond with TYR 576
and two hydrogen bond with GLU 569, while compound-2 is forming one hydrogen bond
with ARG 599, and compound-3 forming 0 hydrogen bond. The anti-uropathogenic
evaluation exhibited that compound one exhibited better activity against S. aureus,
while it was found to possess moderate to good activity against both Gram-positive
bacteria and Gram-negative bacteria excluding S. aureus.
Conclusions: Our study revealed that compound one exhibited better activity than the
standard in case of S. aureus and moderate to good activity against rest of the pathogens.
Molecular docking, physicochemical and bioactivity studies strongly supported the
experimental results. From the well obtained results it was concluded that compound-1
can lead as potential anti-uropathogenic agents.1. Introduction
Multidrug-resistant strains of uropathogenic microorganisms
have evolved as unmanageable infections of urinary tract andemerged as the second most common disease after respiratory
tract infection [1]. Multidrug-resistant pathogens such as
methicillin-resistant Staphylococcus aureus (S. aureus), penicillin
resistant Streptococcus pneumoniae (S. pneumoniae), and
vancomycin-resistant Enterococci, compounded problems in the
therapeutics [2,3]. Quinolines and its derivatives have been known
to possess diverse pharmacological activities such as antibacterial,
antifungal, antimycobacterial, antidepressant, antimalarial,
anticonvulsant, antiviral, anticancer, hypotensive and anti-
inﬂammatory activities [4–11]. Quinine, which is extracted from
Cinchona bark, has provided the basis for the development of
synthetic quinoline-containing drugs, and many of them are
presently available such as chloroquine, amodiaquine and mef-
loquine [12]. Hydrazones owing to their physiological activity and
co-ordination capability yielded a number of pharmacophoresan open access article under the CC BY-NC-ND
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and antifungal activities [13–29]. Some of the hydrazone
derivatives have been found to represent the potential
antimicrobial activity such as 2,5-diformyl-1H-pyrrole bis(me-
than-1-yl-1-ylidene)dimalonohydrazone [30], Benzylidene/2-
aminobenzylidene hydrazides [30], 1,3-benzothiazole-2-yl-
hydrazone [31], metal complexes with 2-acetylpyridine phenox-
yacetyl hydrazone [32], pyrrole dihydrazones and their metal
complexes [33–36], cholic acid hydrazone analogues [37],
macrocyclic bis hydrazone [37], 3-oxido-1H-imidazole-4-
carbohydrazides [38]. On the other hand, the evaluation of
physicochemical parameters of a chemical entity plays a vital
role in generation and escalation of bioactivity of chemical
entity which is obtained by Molinspiration, web based software
[39]. Docking studies were also carried out to ﬁnd out the
interaction of the synthesized compounds with the receptor in
comparison to the standard drug Ciproﬂoxacin. Keeping in
mind the importance of quinoline nucleus and hydrazones
functionality, we designed our research in such a way that the
combination of this functionality together will be important to
enhance the biological activity.
2. Materials and methods
Solvents and organic reagents were purchased from Sigma
Aldrich, Merck (Germany) and were used without further puri-
ﬁcation. Melting points (m.p.) were performed using a Mel-
Temp instrument, and the results were uncorrected. Precoated
aluminium sheets (silica gel 60 F254, Merck Germany) were
used for thin-layer chromatography (TLC) and spots were
visualized under UV light. Elemental analyses were performed
on Heraeus Vario EL III analyzer. Infrared radiation (IR) spectra
were recorded on Perkin–Elmer model 1600 FT-IR RX1 spec-
trophotometer as KBr discs. 1Hydrogen-nuclear magnetic reso-
nance (1H-NMR) and carbon-13 nuclear magnetic resonance
(13C-NMR) spectra were recorded on Bruker AVANCE 300
spectrometer using CDCl3 and dimethyl sulfoxide (DMSO) as
solvents with tetramethylsilane as internal standard. Splitting
patterns are designated as follows; s, singlet; d, doublet; dd,
double doublet; t, triplet; m, multiplet. Chemical shift values are
given in ppm. Electrospray ionisation mass spectrometry (ESI-
MS) was recorded on a Micromass Quattro II triple quadrupole
mass spectrometer.
2.1. General procedure for the synthesis of ethyl-2-
(quinolin-8-yloxy)acetate (A)
A mixture of 8-hydroxyquinoline (10 mmol), ethyl chlor-
oacetate (10 mmol) and potassium carbonate (15 mmol) in dry
acetone (100 mL) was reﬂuxed for 24 h. The reaction mixture
was ﬁltered hot and the solvent was distilled off from the ﬁltrate.
The crude ester thus obtained was puriﬁed by recrystallization
from ethanol.
2.2. General procedure for the synthesis of 2-(quinolin-
8-yloxy)acetohydrazide (B)
A mixture of A (10 mmol) and hydrazine hydrate (99%,
10 mmol) in ethanol (50 mL) was reﬂuxed for 8 h. The solution
on cooling gave a solid mass of hydrazide, which was collected
by ﬁltration, and recrystallized from ethanol.2.3. General procedure for the synthesis of Schiff bases
(1–3)
A mixture of compound B (10 mmol), appropriate aldehyde
(10 mmol) and few drops of glacial acetic acid in ethanol
(50 mL) was reﬂuxed for 12 h. The product was precipitated,
collected by ﬁltration and re-crystallized from ethanol.
(E-)-N0-(4-methoxybenzylidene)-2-(quinolin-8-yloxy)aceto-
hydrazide (1).
Yellow solid; yield: 80%; m.p. 162–164 C Anal. Calc. for
C19H17N3O3: C 68.05, H 5.11, N 12.53%, found C 68.12, H 5.14,
N 12.54%; IR n (cm−1): 3134 (NH), 3011 (Ar, C–H), 1720 (C]
O), 1612 (C]N); 1H-NMR (DMSO) d (ppm): 9.14 (s, 1H, NH),
8.12 (s, 1H, CH]N), 7.87 (d, 1H, J = 8.1 Hz, Ar–H), 7.78 (d, 1H,
J = 8.1 Hz, Ar–H), 7.68 (m, 1H, Ar–H), 7.64 (m, 2H, Ar–H), 7.56
(d, 1H, J = 9.0 Hz, Ar–H), 7.31 (d, 2H, J = 8.0 Hz, Ar–H), 7.24 (d,
2H, J = 8.0 Hz, Ar–H), 5.68 (s, 2H, –CH2–), 3.85 (s, 3H, –OCH3);
13C-NMR (DMSO) d/ppm: 167.6 (C]O), 165.56 (C]N),
160.72, 158.64, 151.63 (Ct), 150.45, 148.53, 139.27, 131.62,
129.90, 129.52, 129.13, 128.41, 127.22, 119.43, 115.33, 112.52,
55.62 (–OCH3), 52.21 (–CH2–); ESI-MS m/z: [M
++H] 336.13.
(E-)-N0-(3,4-dimethoxybenzylidene)-2-(quinolin-8-yloxy)
acetohydrazide (2).
Yellow solid; yield: 84%; m.p. 166–168 C Anal. Calc. for
C20H19N3O4: C 65.74, H 5.24, N 11.50%, found C 65.75, H
5.26, N 11.54%; IR n (cm−1): 3136 (NH), 3017 (Ar, C–H), 1724
(C]O), 1610 (C]N); 1H-NMR (DMSO) d (ppm): 9.10 (s, 1H,
NH), 8.11 (s, 1H, CH]N), 7.89 (d, 1H, J = 8.2 Hz, Ar–H), 7.74
(d, 1H, J = 8.6 Hz, Ar–H), 7.65 (m, 1H, Ar–H), 7.60 (m, 2H,
Ar–H), 7.56 (d, 1H, J = 8.5 Hz, Ar–H), 7.35 (d, 2H, J = 8.0 Hz,
Ar–H), 7.30 (d, 2H, J = 7.0 Hz, Ar–H), 5.60 (s, 2H, –CH2–),
3.81 (s, 3H, –OCH3), 3.79 (s, 3H, –OCH3);
13C-NMR (DMSO)
d/ppm: 167.63 (C]O), 165.55 (C]N), 160.76, 158.62, 151.62,
150.47, 148.50, 139.23, 131.61, 129.90, 129.51, 129.13, 128.40,
127.29, 119.43, 115.37, 112.56, 55.60 (–OCH3), 52.2 (–CH2–);
ESI-MS m/z: [M++H] 366.14.
(E-)-N0-(3,4,5-methoxybenzylidene)-2-(quinolin-8-yloxy)
acetohydrazide (3).
Yellow solid; yield: 83%; m.p. 170–172 C Anal. Calc. for
C21H21N3O5: C 63.79, H 5.35, N 10.63%, found C 63.76, H 5.35,
N 10.65%; IR n (cm−1): 3130 (NH), 3017 (Ar, C–H), 1725 (C]
O), 1614 (C]N); 1H-NMR (DMSO) d (ppm): 9.10 (s, 1H, NH),
8.14 (s, 1H, CH]N), 7.82 (d, 1H, J = 8.6 Hz, Ar–H), 7.76 (d, 1H,
J = 8.8 Hz, Ar–H), 7.65 (m, 1H, Ar–H), 7.62 (m, 2H, Ar–H), 7.54
(d, 1H, J = 9.5 Hz, Ar–H), 7.34 (d, 2H, J = 8.4 Hz, Ar–H), 7.27 (d,
2H, J = 7.0 Hz, Ar–H), 5.63 (s, 2H, –CH2–), 3.85 (s, 3H, –OCH3),
3.80 (s, 3H, –OCH3), 3.78 (s, 3H, –OCH3);
13C-NMR (DMSO) d/
ppm: 167.67 (C]O), 165.52 (C]N), 160.71, 158.63, 151.60,
150.40, 148.55, 139.24, 131.63, 129.97, 129.56, 129.11, 128.49,
127.27, 119.45, 115.33, 112.52, 55.61 (–OCH3), 52.23 (–CH2–);
ESI-MS m/z: [M++H] 336.13.
2.4. Physicochemical properties [40]
Physico-chemical properties of compounds 1–3 and cipro-
ﬂoxacin were checked with the help of software Molinspiration
physicochemical properties calculator available online (www.
molinspiration.com). The properties of partition coefﬁcient
(log P), molar refractivity, molecular weight, number of heavy
atoms, number of hydrogen donor, number of hydrogen acceptor
and number of violation were calculated.
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The compounds and standard were also checked for the
bioactivity score by calculating the activity score for GPCR
ligand, ion channel modulator, kinase inhibitor, nuclear receptor
ligand. All the parameters were checked with the help of soft-
ware Molinspiration drug-likeness score online (www.
molinspiration.com). Drug likeness score of each compounds
was calculated and compared with the speciﬁc activity of each
compound, and the results were compared with standard drug.
2.6. Biological screening
2.6.1. Isolation and characterization of uropathogens
2.6.1.1. Collections of urine specimen
Midstream urine samples were aseptically collected from
patients suspected to have urinary tract infections attending Al-
Dawadmi General Hospital, Saudi Arabia. Midstream urine
samples (n = 10) were collected in a sterile container. The
specimens were transported to the clinical microbiology labo-
ratory of College of Medicine, Al-Dawadmi with the support of
ice packs and appropriately stored in refrigerator at 4 C until
analyses were carried out.
2.6.1.2. Total aerobic plate count
The total aerobic plate count of the urine specimens were
carried out using serial dilution-pour plate technique. Serial di-
lutions were carried out by pipetting 1 mL of the urine sample
into 9 mL of normal saline solution and then it was serially
diluted to 10−6. Following inoculation the culture plates were
incubated for overnight at 37 C and number of CFU was
recorded using a colony counter.
2.6.1.3. Selective isolation of pure culture
The urine specimens (n = 4) showing signiﬁcant bacteriuria
based on total aerobic plate counts were inoculated aseptically in
different selective media such as Mac Conkey agar, eosin meth-
ylene blue agar, blood agar and mannitol salt agar. All the inocu-
lated plates were incubated at 37 C for overnight. Pure cultures
were recovered using repeated periodic sub-culturing method.
2.6.1.4. Maintenance and preservation of pure culture
Pure cultures obtained were maintained in refrigerator for
further microbiological analyses on agar slant at 4

C and were
revived periodically. They were preserved in glycerol stocks
at −20

C freezer.
2.6.1.5. Morphological and biochemical characterization
of pure cultures
Characterization of all the isolates was carried out on the
basis of their morphological features and biochemical charac-
teristics. The biochemical tests were carried out using IMViC
test, catalase test, urease test, coagulase test and gas production
tests to identify the isolates.
2.6.2. Anti-uropathogenic activity
Organism culture and in vitro screening for anti-uropathogenic
activity was done by the disk diffusion method with minor mod-
iﬁcations. The isolated and biochemically characterized Escher-
ichia coli (E. coli), Proteus mirabilis (P. mirabilis), S. aureus andStaphylococcus epidermidis (S. epidermidis) were subcultured in
nutrient agar medium and incubated for 18 h at 37 C. Following
the incubation the bacterial cells were suspended, according to the
McFarland protocol in saline solution to produce a suspension of
about 105 CFU/mL. About 10 mL of this suspension was mixed
with 10 mL of sterile antibiotic agar at 40 C and poured on to an
agar plate in a laminar ﬂow cabinet. Five paper disks (6.0 mm
diameter) were ﬁxed onto nutrient agar plate. One milligram of
each test compound was dissolved in 100 mL DMSO to prepare
stock solution. From the stock solution different dilutions of each
test compound were prepared and poured over disk plate. Cipro-
ﬂoxacin was used as a standard drug (positive control). DMSO
poured disk was used as negative control. The susceptibility of the
bacteria to the test compounds was determined by the formation of
an inhibitory zone after 18 h of incubation at 36 C. The zone of
inhibition was calculated by antibiotic zone scale. The results were
compared with the negative and positive controls and the zone of
inhibitions was measured at theminimum inhibitory concentration
(MIC). The MIC was evaluated by the macro-dilution test using
standard inoculums of 105 CFU/mL. Serial dilutions of the test
compounds, previously dissolved in DMSOwere prepared to ﬁnal
concentrations of 400, 200, 100, 50, 12.5, 6.25 and 3.125 mg/mL.
To each tube was added 100mL of a 24-h-old inoculum. TheMIC,
deﬁned as the lowest concentration of the test compound, which
inhibits the visible growth after 18 h, was determined visually after
incubation for 18 h, at 37 C.
2.7. In silico molecular docking studies
The ligands were drawn in ChemDraw Ultra 8.0 (ChemO-
fﬁce package) and were converted to energy minimized 3D
structures for in silico protein–ligand docking using AutoDock
Tools [42,43]. All the heteroatoms were removed from the
2VF5.PDB, to make complex receptor free of any ligand
before docking. AutoDock requires pre-calculated grid maps,
one for each atom type, present in the ligand being docked as it
stores the potential energy arising from the interaction with
macromolecule. This grid must surround the region of interest
(active site) in the macromolecule. In the present study, the
binding site was selected based on the amino acid residues,
which are involved in binding with glucosamine-6-phosphate of
GlcN-6-P synthase as obtained from PDB with ID 2VF5 which
would be considered as the best accurate active region as it is
solved by experimental crystallographic data [42,43]. Therefore,
the grid was centered at the region including all the 12 amino
acid residues (Ala602, Val399, Ala400, Gly301, Thr302,
Ser303, Cys300, Gln348, Ser349, Thr352, Ser347 and
Lys603) that surround active site as in Figures 1 and 2. The
grid box size was set at 70, 64, and 56 A

for x, y and z
respectively, and the grid center was set to 30.59, 15.822 and
3.497 for x, y and z respectively, which covered all the 12 amino
acid residues in the considered active pocket. Docking software
AutoDock 4.2 Program supplied with AutoGrid 4.0 and Auto-
Dock 4.0 was used to produce grid maps. The spacing between
grid points was 0.375 Å. The Lamarckian genetic algorithm was
chosen to search for the best conformers. During the docking
process, a maximum of 10 conformers was considered for each
compound. All the AutoDock docking runs were performed in
Intel Core i3-2330M CPU @ 2.20 GHz of Sony system, with
2 GB DDR2 RAM. AutoDock 4.0 was compiled and run under
Microsoft Windows-7 operating system.
Figure 2. All 12 amino acid residues of active pocket (which were
involved in binding with glucosamine-6-phosphate of GlcN-6-P synthase as
obtained from PDB with ID 2VF5).
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Figure 4. Structure of the compounds 1–3.
Figure 1. Crystal structure of X chain of GlcN-6-P synthase complex with
glucosamine-6-phosphate.
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3.1. Chemistry
The synthetic route for (E-)-N0-(substituted-benzylidene)-2-
(quinolin-8-yloxy) acetohydrazide (1–3) is shown in Figure 3,
which completes in three steps. In the ﬁrst ethyl-2-(quinolin-8-
yloxy)acetate (A) was formed using ethyl chloroacetate and
potassium carbonate. TLC conﬁrmed the conversion and 1H
NMR helped in establishing the structure. In addition the signals
at 1.11–1.26 ppm, a triplet for CH3 and 4.10–4.26 ppm, a quartet
for CH2 proton conﬁrmed the condensation reaction. In second
step on reﬂuxing in ethanol with hydrazine hydrate gave rise to
condensation with hydrazine hydrate to get the acetohydrazide.
2-(quinolin-8-yloxy)acetohydrazide (B). A singlet at around
9.52 ppm conﬁrmed this conversion. In the third step formation
of (E-)-N0-(substituted-benzylidene)-2-(quinolin-8-yloxy) aceto-
hydrazide (1–3) achieved by simple reaction of B withappropriate aldehyde. The structure of (E-)-N0-(substituted-
benzylidene)-2-(quinolin-8-yloxy) acetohydrazide (1–3) are
presented in Figure 4. The reaction was monitored by TLC and
structures were elucidated using various spectroscopic tech-
niques. The purity of compounds was established from sharp
melting points and elemental analysis data. The detailed spec-
troscopic data were represented in experimental part.
3.2. Physicochemical properties
Lipinski's rule of ﬁve states that, in general, an orally active
drug has not more than 5 hydrogen bond donors (OH and NH
groups), not more than 10 hydrogen bond acceptors (notably N
and O), molecular weight under 500 g/mol, partition coefﬁcient
log P less than 5, number of violation less than 4 [41]. All the
compounds were found in compliance with Lipinski's rule of
ﬁve and the results are reported in Table 1.
3.3. Bioactivity score
The bioactivity score was calculated for GPCR ligand, ion
channel modulator, kinase inhibitor, nuclear receptor ligand,
protease inhibitor and enzyme inhibitor. For average organic
molecule the probability of bioactivity score is more than 0.00
then it is active, −0.50 to 0.0 then moderately active and if less
than −0.50 then inactive. Here in our study all the synthesized
compounds 1–3 were subjected for bioactivity score presented in
Table 2.
3.3.1. Isolation and characterization of uropathogens
The most commonly used criterion for deﬁning signiﬁcant
bacteriuria is the presence of  105 CFU/mL of urine specimen.
Total aerobic plate counts of four out of 10 mid-stream urine
Table 1
Representing the physicochemical properties of all the synthesized compounds (1–3) and ciproﬂoxacin.
Compounds Physicochemical property score
miLogP TPSA Natoms MW nON nOHNH Nviolations Nrotb Volume
1 2.682 72.822 25.0 335.363 6 1 0 6 301.266
2 2.672 82.056 27.0 365.389 7 1 0 7 326.812
3 2.657 91.290 29.0 395.415 8 1 0 8 352.357
Ciproﬂoxacin −0.701 74.569 24.0 331.347 6 2 0 3 285.460
miLogP: Partition coefﬁcient; TPSA: Topological polar surface area; Natoms: Number of heavy atoms; MW: Molecular weight; nON: Number of
hydrogen bond acceptor; nOHNH: Number of hydrogen bond donors; Nviolations: Number of violations; Nrotb: Number of ratable bonds.
Table 2
Representing the bioactivity score of all the synthesized compounds (1–3) and ciproﬂoxacin.
Compounds Bioactivity score
GPCR ligand Ion channel modulator Kinase inhibitor Nuclear receptor ligand Protease inhibitor Enzyme inhibitor
1 −0.34 −0.69 −0.39 −0.66 −0.50 −0.32
2 −0.33 −0.65 −0.37 −0.64 −0.50 −0.30
3 −0.32 −0.62 −0.34 −0.65 −0.48 −0.28
Ciproﬂoxacin 0.12 −0.04 −0.07 −0.19 −0.21 0.28
Gram posiƟve
Gram negaƟve
Figure 5. The Gram reaction results against the uropathogens.
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specimen and the other six specimens were showing insigniﬁ-
cant bacteriuria.
Urine (CFU/mL) = number of CFU × dilution factor/volume
(0.1 mL) of the diluted sample taken.
Four pure bacterial isolates recovered were morphologically
and biochemically characterized and designated as E. coli,
S. aureus, S. epidermidis and P. mirabilis (Table 3 and
Figure 5).
3.3.2. Anti-uropathogenic activity
All the compounds (E-)-N0-(substituted-benzylidene)-2-(qui-
nolin-8-yloxy) acetohydrazide (1–3) were screened for their
in vitro anti-uropathogenic activity against the isolated Gram-
positive and Gram-negative bacteria. Four different cultures,
two each of Gram-negative (E. coli and P. mirabilis) and Gram-
positive (S. aureus and S. epidermidis) were treated with syn-
thesized compounds using disk diffusion method [44]. The
results were compared with positive control, the standard drug
ciproﬂoxacin and negative control, the DMSO poured disk.
MIC was evaluated by macrodilution test using standard
inoculums of 10−5 CFU/mL. The susceptibility of the bacteria
to the test compounds was determined by the formation of an
inhibitory zone after 18 h of incubation at 37 C. TheTable 3
Representing the results of morphological and biochemical characterization
Uropathogens
Coagulase Catalase Indole MR VP Citrate Urease Gas
product
S. aureus + + − + + − − +
S. epidermidis − + − + + − − +
E. coli − + + + − − − +
P. mirabilis − + − + − + + −
MR: Methyl red test; VP: Voges–Proskauer test.inhibition zones (mm) of each compound and the minimum
concentration at which the inhibition zones appeared are
presented in Tables 4 and 5, respectively.
3.4. Molecular docking studies
Considering the well obtained in vitro results, it was thought
worthy to perform molecular docking studies, hence screening
the compounds, inculcating both in silico and in vitro results.of uropathogens.
Test
ion
Swarming on blood
agar medium
Shape Size Arrangement Gram
reaction
− Round
(Coccus)
Small Cluster +
− Round
(Coccus)
Small Cluster +
− Rod Shaped
(Bacillus)
Small Single −
+ Rod Shaped
(Bacillus)
Small Single or
Paired
−
Table 5
Representing MIC of the compounds (1–3).
Compounds Gram positive Gram negative
S. aureus S. epidermidis P. mirabilis E. coli
1 6.25 3.125 6.25 12.5
2 12.50 12.500 12.50 25.0
3 12.50 6.250 12.50 12.5
Ciproﬂoxacin 6.25 3.125 6.25 12.5
Ciproﬂoxacin was used as standard drug.
Table 4
Anti-uropathogenic activity of the synthesized compounds (1–3) (mm).
Compounds Gram-positive Gram-negative
S. aureus S. epidermidis P. mirabilis E. coli
1 21.55 ± 0.56 21.14 ± 0.44 20.43 ± 0.61 21.82 ± 0.50
2 19.16 ± 0.84 18.35 ± 0.62 20.72 ± 0.99 22.34 ± 0.33
3 18.33 ± 0.53 17.57 ± 0.24 18.36 ± 0.22 20.44 ± 0.11
Ciproﬂoxacin 21.46 ± 0.31 22.64 ± 0.54 22.24 ± 0.30 23.82 ± 0.47
DMSO − − − −
Ciproﬂoxacin was used as positive control and DMSO as negative
control measured by the Holo zone test.
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ative and automated docking studies with newly synthesized
candidate lead compounds was performed to determine the best
in silico conformation. The Lamarckian genetic algorithm,
inculcated in the docking program AutoDock 4.2, was employed
to satisfy the purpose. Figure 1 shows the native crystal structure
of GlcN-6-P synthase (X chain) in complex with glucosamine-6-
phosphate obtained from Protein Data Bank (http://www.pdb.
org/pdb/home/home.do) with the PDB ID 2VF5 which was
resolved at 2.90 A

using X-ray diffraction [42,43] (Figure 3). All
the three synthesized molecules were docked. Figure 6 repre-
sents the docked images of all the compounds including the
considered standard drug ciproﬂoxacin.Figure 6. The docked images of the synthesized compounds with the GlcN-64. Discussion
The structure elucidation of (E-)-N0-(substituted-benzyli-
dene)-2-(quinolin-8-yloxy) acetohydrazide (1–3) was done using
various spectroscopic techniques such as Fourier transform
infrared spectroscopy, 1H-NMR, 13C-NMR spectral data. The
reaction was monitored by TLC and structures were elucidated
using various spectroscopic techniques. The purity of com-
pounds was established from sharp melting points and elemental
analysis data. Assignment of selected characteristic IR bands
provides signiﬁcant indications for the formation of the (1–3).
The band around 1610–1614, 1720–1725 cm−1 represents the
stretching frequency of C]N and C]O groups, respectively.
Similarly the band around 3130-3136 cm-1 was assigned to N–H
respectively. The structures of compounds were further estab-
lished on the basis of 1H and 13C-NMR. In 1H-NMR, besides the
aromatic region, four prominent signals were observed. The
presence of singlet around (9.10–9.14) ppm was assigned to NH
proton. Another singlet around (8.11–8.14) ppm due to HC]N
proton also conﬁrms the formation of the compounds (1–3). The
carbonyl carbon signal was found downshifted to (167.63–
167.67) ppm and the nitrile carbon signals due to H–C]N
found around 165.52–165.56 ppm which provide strong
recommendation for the formation of these compounds. In
addition to NMR, the compounds were subjected to ESI-MS
analysis for detecting the molecular mass of the compounds.
Results obtained for structure elucidation of all the synthesized
compounds provide strong recommendation for the complete
conversion of these compounds and also supported by the re-
ported literature [9,10,25]. Physicochemical calculations exhibited
that all the compounds were found to compliance with Lipinski's
rule of ﬁve similar to the results obtained by Verma [40]. The
bioactivity score was calculated for GPCR ligand, ion channel
modulator, kinase inhibitor, nuclear receptor ligand, protease
inhibitor and enzyme inhibitor. Bioactivity score results
revealed that the compounds have bioactivity score
between −0.50 and 0.00 which states that these compounds
are moderately active according to the bioactivity score
evaluation parameters as discussed in the study of Verma [40].
Molecular docking studies state that compound one and the-P synthase.
Essa Ajmi Alodeani et al./Asian Pac J Trop Biomed 2015; 5(8): 676–683682ciproﬂoxacin are forming the hydrogen bond with TYR 576, and
the results obtained from docking study are found in accordance
with the results obtained experimentally and strongly supported
by the reported literature [45,46]. The zone of inhibition was
measured at the MIC. Anti-uropathogenic activity of the syn-
thesized compounds was evaluated on uropathogens following
isolation and characterization. About 50% of the total isolates
were found to be of Gram-negative culture while 50% was
showing Gram-positive characteristics similar to the reported
results [47]. When zone of inhibition was compared with the
standard drug, it was observed that compound two and three
were found to show 80% resemblance with the standard drug
only in case of E. coli and exhibiting moderate to good
activity against the rest of the pathogens. On the other hand,
compound one exhibited better activity against S. aureus,
while it was found to possess moderate to good activity
against both Gram-positive bacteria and Gram-negative bacte-
ria excluding S. aureus. The results were found in accordance
with the study carried out by Shakir et al. [48]. The importance of
such work lies in the possibility that the new compound might
be more effective against bacteria for which a thorough
investigation regarding the structural activity relationship,
toxicity and the biological effects would be helpful in
designing more potent antibacterial agents for therapeutic use.
The (E-)-N0-(substituted-benzylidene)-2-(quinolin-8-yloxy)
acetohydrazide (1–3) was synthesized starting from the simple
chemical molecules and their structures were elucidated by
various spectroscopic techniques. All the compounds were
screened for anti-uropathogenic activity against the isolated and
characterized Gram-positive and Gram-negative bacteria. Re-
sults revealed that compound one exhibited better activity than
the standard in case of S. aureus and moderate to good activity
against rest of the pathogens. While compound two and three
were found moderate to good activity against all Gram-positive
and Gram-negative bacteria. All the compounds follow the
Lipinski's rule of ﬁve and bioactivity score is also in accordance
with the experimental results except only in case of compound
one. To support the results obtained experimentally docking
studies was done and docking results are found in accordance
with the experimental results.Conﬂict of interest statement
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